Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVB-3567 SAD/MAD and Food Effect Study in Healthy Participants and Participants With Acne
NCT06989840Phase 1Recruiting
- Sponsor
- Sagimet Biosciences
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of TVB-3567 in acne vulgaris (4 arms), sponsored by Sagimet Biosciences. Primary endpoints: Incidence of adverse events and serious adverse events, Area under the plasma concentration-time curve from time zero to time t at Day 4 and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
TVB-3567
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06989840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989840.